Xalkori (crizotinib) — United Healthcare
Central Nervous System (CNS) Cancers
Initial criteria
- Diagnosis of metastatic brain cancer from NSCLC
- Tumor is ALK-positive OR ROS1-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Xalkori therapy
Approval duration
12 months